1. Cancer Discov. 2022 Apr 1;12(4):879-880. doi:
10.1158/2159-8290.CD-NB2022-0009.

First Drug Approved for Rare Eye Cancer.

[No authors listed]

Tebentafusp, the first drug shown to extend overall survival in people with 
uveal melanoma, was greenlighted by the FDA in late January to treat patients 
with inoperable or metastatic forms of the aggressive eye cancer. The drug is 
also the first T-cell receptor therapy to reach the market.

Â©2022 American Association for Cancer Research.

DOI: 10.1158/2159-8290.CD-NB2022-0009
PMID: 35115315 [Indexed for MEDLINE]
